When Deanna Hogue needed a doctor on a holiday weekend, she reached her physician on his cell phone. Dr. James Gardner III immediately responded. Hogue and her husband, Chad, are among nearly 400 ...

A memorial service will be held at 11:00 a.m. on Saturday, June 28, 2025 at Lower Brandywine Presbyterian Church (101 Old Kennett Rd, Wilmington, DE 19807). Visitation will begin at 10:00 a.m.

WILMINGTON, DE, UNITED STATES, June 18, 2025 /EINPresswire / -- According to a new report published by Allied Market Research, titled,“Feruli ...

Now through June 21, the sights, sounds and smells of a summertime fair will be filling the air in Downingtown when Saint ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

The Financial Times reports Merck submitted a nonbinding offer that valued MoonLake at more than $3 billion earlier this year. The offer was rejected, but talks could be revived, the FT said.

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck (NYSE:MRK) recently announced a third-quarter dividend affirmation of $0.81 per share, underscoring its commitment to returning value to shareholders. Over the past week, the company's stock ...

(Reuters) -Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out why MRK stock is a Strong Buy.

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.